| Company* (Country; Symbol) |
Company (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
| I. MODIFIED AGREEMENTS | |||
| Agendia BV* (the Netherlands) | Agilent Technologies Inc. (NYSE:A) | Extended supply agreement and collaboration on the development of new in vitro diagnostic tests | The firms will collaborate on developing cancer diagnostic tests that will be run on Agilent microarrays (4/22) |
| Alseres Pharmaceuticals Inc. (ALSE) | BioAxone Therapeutics Inc.* (Canada) | Agreement for Alseres to exercise an option to amend the company's Cethrin license agreement | That option may be exercised upon payment by Alseres of an option fee of $7M on or before Oct. 27; the pre-commercial milestone payments will be reduced from $25M to $7M payable on or before ec. 31, 2009; sales-based royalties will be reduced from 10-12% to 4% for spinal cord injury and 1% for all other indications (5/6) |
|
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.NYSE = New York Stock Exchange. | |||
